Sangamo Therapeutics (SGMO) Set to Announce Earnings on Thursday

Sangamo Therapeutics (NASDAQ:SGMO) will be issuing its quarterly earnings data after the market closes on Thursday, November 8th. Analysts expect the company to announce earnings of ($0.13) per share for the quarter.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). Sangamo Therapeutics had a negative net margin of 105.65% and a negative return on equity of 26.36%. The business had revenue of $21.42 million during the quarter, compared to analyst estimates of $21.43 million. During the same quarter in the previous year, the firm posted ($0.17) earnings per share. The firm’s quarterly revenue was up 159.6% on a year-over-year basis. On average, analysts expect Sangamo Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Shares of NASDAQ SGMO traded down $0.05 during midday trading on Friday, reaching $13.91. The company’s stock had a trading volume of 58,458 shares, compared to its average volume of 1,616,949. The company has a current ratio of 7.24, a quick ratio of 7.24 and a debt-to-equity ratio of 0.07. Sangamo Therapeutics has a fifty-two week low of $11.45 and a fifty-two week high of $27.50. The company has a market cap of $1.26 billion, a price-to-earnings ratio of -19.63 and a beta of 2.97.

SGMO has been the subject of several research analyst reports. Zacks Investment Research downgraded shares of Sangamo Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 17th. Cowen restated a “buy” rating on shares of Sangamo Therapeutics in a research report on Monday, July 23rd. Wedbush restated a “hold” rating and set a $9.00 price objective on shares of Sangamo Therapeutics in a research report on Tuesday, July 24th. BidaskClub downgraded shares of Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, July 26th. Finally, ValuEngine downgraded shares of Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, September 6th. One analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $21.00.

In related news, Director H Stewart Parker purchased 2,000 shares of the stock in a transaction dated Friday, September 7th. The stock was bought at an average cost of $13.52 per share, for a total transaction of $27,040.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Kathy Yi sold 5,000 shares of the company’s stock in a transaction on Thursday, August 16th. The stock was sold at an average price of $15.39, for a total transaction of $76,950.00. Following the transaction, the chief financial officer now owns 12,250 shares of the company’s stock, valued at $188,527.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 30,000 shares of company stock valued at $430,950. Company insiders own 1.20% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.

Further Reading: What is the Dow Jones Industrial Average (DJIA)?

Earnings History for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply